{"id":937,"date":"2021-04-07T10:13:20","date_gmt":"2021-04-07T10:13:20","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=937"},"modified":"2021-04-07T10:13:20","modified_gmt":"2021-04-07T10:13:20","slug":"26-mar-2021-tenofovirdf-may-be-an-effective-antiviral-in-the-treatment-of-covid-19","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/26-mar-2021-tenofovirdf-may-be-an-effective-antiviral-in-the-treatment-of-covid-19\/","title":{"rendered":"(26 Mar 2021) TenofovirDF- may be an effective antiviral in the treatment of COVID-19"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Tenofovir-DF versus Hydroxychloroquine in the Treatment of Hospitalized Patients with COVID-19: An Observational Study (TEDHICOV)<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2021.03.24.21252635v1<\/p>\n<div id=\"sec-3\" class=\"subsection\">\n<p id=\"p-4\" class=\"\">NCT04812496- 104 patients were included: 36 in the HCQ group and 68 in the TDF group. The unadjusted primary outcomes were: LOS (length of stay) 16.6 \u00b1 12.1 for HCQ versus 12.2 \u00b1 7.0 days for TDF (p = o.o102); need for admission to ICU \/ mechanical ventilation (MV): 61.1% for HCQ versus 11.8% for TDF (p = o.ooo); and mortality: 50.0% for HCQ and 8.8% for TDF (p = o.ooo).&nbsp; When the outcomes were adjusted for these baseline differences, in the multiple regression model for LOS, it was found that TDF decreased the hospital stay by 6.10 days (C.I.: \u221211.97 to \u22122.40, p = o.o42); In the logistic regression model for the need for ICU \/ MV, it was found that the use of TDF had an O.R. of 0.15 (C.I.: 0.03-0.76, p = o.o22); and for the Cox proportional hazards model for mortality, the H.R. was 0.16 for TDF (C.I.: 0.03-0.96, p = o.o41). In the estimation model of the treatment effects by regression adjustment, it was found that TDF decreased the stay by \u22126.38 days (C.I.: \u221212.34 to \u22120.42, p = o.o36); the need for ICU \/ MV at \u221241.74% (C.I.: \u221263.72 to \u221219.7, p = o.ooo); and mortality by \u221235.22% (C.I.: \u221256.47 to \u221213.96, p = o.oo1). TDF may be an effective antiviral in the treatment of COVID-19. Some of its advantages include: its wide availability, cost and oral presentation. Randomized clinical trials are imperatively required to confirm this possibility.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tenofovir-DF versus Hydroxychloroquine in the Treatment of Hospitalized Patients with COVID-19: An Observational Study (TEDHICOV) https:\/\/www.medrxiv.org\/content\/10.1101\/2021.03.24.21252635v1 NCT04812496- 104 patients were included: 36 in the HCQ group and 68 in the TDF group. The unadjusted primary outcomes were: LOS (length of&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/26-mar-2021-tenofovirdf-may-be-an-effective-antiviral-in-the-treatment-of-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(26 Mar 2021) TenofovirDF- may be an effective antiviral in the treatment of COVID-19&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,118],"tags":[119],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/937"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=937"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/937\/revisions"}],"predecessor-version":[{"id":938,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/937\/revisions\/938"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}